Carlizumab Plus Sovantinib in Second-line Treatment of Advanced or Metastatic Cholangiocarcinoma

NCT05697237 · clinicaltrials.gov ↗

NA

Phase

UNKNOWN

Status

60

Enrollment

OTHER

Sponsor class

Conditions

Cholangiocarcinoma

Interventions

DRUG: Carrelizumab
DRUG: Solfantinib

Sponsor

First Affiliated Hospital Xi'an Jiaotong University